ResearcherFirst Affiliated Hospital Zhejiang UniversityActive in the last 2 years

Yifan Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-6079-5895; OpenAlex author ID A5102376160. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 4

Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS G12D protein to cancer-associated fibroblasts. Co-author DOI 10.1016/j.ymthe.2025.01.023 ↗
Inhibition of DEF-p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer. Co-author DOI 10.1002/advs.202401845 ↗
Deciphering extracellular vesicles protein cargo in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2024.189142 ↗
Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tingbo Liang · 4 shared papers, 2023–2025 · strength 0.84
Xueli Bai · 4 shared papers, 2023–2025 · strength 0.84
Xinyuan Liu · 2 shared papers, 2024–2025 · strength 0.51
- Paper Deciphering extracellular vesicles protein cargo in pancreatic cancer. DOI 10.1016/j.bbcan.2024.189142 ↗
- Paper Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS G12D protein to cancer-asso… DOI 10.1016/j.ymthe.2025.01.023 ↗
Jiaqi Yang · 2 shared papers, 2024–2025 · strength 0.45
- Paper Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS G12D protein to cancer-asso… DOI 10.1016/j.ymthe.2025.01.023 ↗
- Paper Inhibition of DEF-p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer. DOI 10.1002/advs.202401845 ↗
Sicong Huang · 1 shared paper, 2024 · strength 0.20
- Paper Inhibition of DEF-p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer. DOI 10.1002/advs.202401845 ↗
Zhengtao Hong · 1 shared paper, 2023 · strength 0.14
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021 ↗
Hanshen Yang · 1 shared paper, 2023 · strength 0.14
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021 ↗
Lihong He · 1 shared paper, 2023 · strength 0.14
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021 ↗
Kang Sun · 1 shared paper, 2023 · strength 0.14
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021 ↗
Xiaozhen Zhang · 1 shared paper, 2023 · strength 0.14
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021 ↗
Mengyi Lao · 1 shared paper, 2023 · strength 0.14
- Paper Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-… DOI 10.1016/j.ymthe.2023.07.021 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.